| HOME >> BIOLOGY >> TECHNOLOGY |
Adj. EBITDA EPS - diluted 0.19 (0.02) N/A
Reconciliation from Net Income to Adjusted EBITDA:
(in thousands, except per share data)
Nine Months Ended September 30
I-Flow Predecessor
2008 2007 2007
Net Income $8,700 $(928) $3,604
Adjustments:
Interest expense 2,828 33 (237)
Interest income (14) (3,534) -
Income tax expense 399 752 2,460
Depreciation -- Pumps 2,908 - 2,307
Depreciation -- Other 133 - 125
Amortization 1,370 - -
EBITDA $16,325 $(3,677) $8,259
Adjustments:
(Gain) loss on derivatives (8,665) 675 -
Stock based compensation 1,166 1,490 305
Adj. EBITDA $8,826 $(1,512) $8,564
Adj. EBITDA EPS - basic 0.50 (0.08) N/A
Adj. EBITDA EPS - diluted 0.47 (0.08) N/A
About InfuSystem Holdings, Inc.
InfuSystem is the leading provider of ambulatory infusion pumps and
associated clinical services for oncology practices and their patients in
the U.S. These pumps allow for the gradual delivery of a drug over a period
of days in the privacy of one's home, compared to bolus infusion
chemotherapy treatments that are given in a single high dose over a short
period of time. Improved efficacy of the drugs, patient comfort,
reimbursement to doctors for appropriate services and continuity of care
all play a role in the grow
'/>"/>
| SOURCE InfuSystem Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved |